^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Melanoma
    Drug:Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Excerpt:
    Encorafenib plus binimetinib and encorafenib monotherapy showed favourable efficacy compared with vemurafenib.
    DOI:
    doi.org/10.1016/S1470-2045(18)30142-6
    Trial ID:
    COLUMBUS; 2013-001176-38
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

    Excerpt:
    ...Presence of BRAF V600E or V600K mutation in tumor tissue prior to randomization...
    Trial ID:
    COLUMBUS